U.S. Court of Appeals for the Fourth Circuit, 2016

United States ex rel. Palmieri v. Alpharma, Inc.

U.S. Court of Appeals for the Fourth Circuit · Decided April 26, 2016 · Diaz, Duncan, Gregory

647 F. App'x 166

Counsel

Anna C. Dover, Rolando G. Marquez, Milberg, LLP, New York, New York; John B. Isbister, Jaime W. Luse, Tydings & Rosenberg, LLP, Baltimore, Maryland, for Appellant. Steven J. Menashi, Kirkland & Ellis, LLP, New York, New York; John C. O’Quinn, Devin A. DeBacker, Kirkland & Ellis LLP, Washington, D.C., for Appellees.

Cases that cite this one

4 later published cases cite this decision.

Nephew Mini Market, LLC. v. United States (District Court, D. Maryland 2022)
Marshall v. University of TN Medical Center Home Care Services, LLC (District Court, E.D. Tennessee 2021)
Maharaj v. The Estate of Charles Howard Zimmerman (District Court, D. Maryland 2020)
Maharaj v. The Estate of Charles Howard Zimmerman (District Court, D. Maryland 2019)

This list shows which later cases cite this one. It does not say how they treated it, and no review of that has been done. Not a substitute for Shepard’s or KeyCite — verify before relying.

Opinion of the Court

Vacated and remanded by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Relator Jerome Palmieri appeals the district court’s dismissal of his qui tam complaint against his former employer, Alpharma, Inc., and associated companies (collectively, “Defendants”), under the False Claims Act (“FCA”). The district court dismissed Palmieri’s complaint pursuant to Fed.R.Civ.P. 9(b), for failure to plead his claims of fraud with sufficient particularity. In so ruling, the district court did not address Defendants’ arguments that Palmieri’s claims were precluded by the FCA’s first-to-file bar, 31 U.S.C. § 3730(b)(5) (2006),* and public-disclosure bar, 31 U.S.C. § 3730(e)(4)(A) (2006), amended by Patient Protection & Affordable Care Act, Pub.L. No. 111-148, tit. X,. sec. 10104(j)(2), 124 Stat. 119, 901-02 (2010).

Under the pre-2010 version of § 3730 that governs Palmieri’s action, see United States ex rel. May v. Purdue Pharma L.P., 737 F.3d 908, 915 (4th Cir. 2013) (recognizing “that the 2010 FCA amendments may not be applied to cases arising before the effective date of the amendments”), both the first-to-file and public-disclosure defenses are jurisdictional in na*167ture, see id. at 914-18, 920 (§ 3730(e)(4)(A)); United States ex rel. Carter v. Halliburton Co., 710 F.3d 171, 181 (4th Cir. 2013) (§ 3730(b)(5)), rev’d in part on other grounds, Kellogg Brown & Root Servs., Inc. v. United States ex rel. Carter, — U.S.-, 135 S.Ct. 1970, 191 L.Ed.2d 899 (2015). We conclude, therefore, that the district court was obligated to consider both defenses before assessing the sufficiency of Pahnieri’s complaint. Accordingly, we vacate the district court’s order and remand this case for consideration in the first instance of whether the FCA’s first-to-file bar or public-disclosure bar deprived the district court of subject-matter jurisdiction.

We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.

VACATED AND REMANDED.

The current version of § 3730(b)(5) is identical to the version in effect at the time Palmieri’s darais arose.

Case-law data current through December 31, 2025. Source: CourtListener bulk data.